2,435 Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Vontobel Holding Ltd.

Vontobel Holding Ltd. lessened its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 40.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,583 shares of the biopharmaceutical company’s stock after selling 2,435 shares during the quarter. Vontobel Holding Ltd.’s holdings in Alnylam Pharmaceuticals were worth $884,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ALNY. TD Waterhouse Canada Inc. lifted its stake in Alnylam Pharmaceuticals by 26.2% in the third quarter. TD Waterhouse Canada Inc. now owns 2,304 shares of the biopharmaceutical company’s stock worth $532,000 after purchasing an additional 479 shares during the last quarter. TB Alternative Assets Ltd. bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $1,076,000. Assenagon Asset Management S.A. grew its stake in shares of Alnylam Pharmaceuticals by 8.1% during the third quarter. Assenagon Asset Management S.A. now owns 168,320 shares of the biopharmaceutical company’s stock valued at $41,531,000 after buying an additional 12,625 shares during the last quarter. Fortitude Family Office LLC grew its stake in shares of Alnylam Pharmaceuticals by 10.5% during the third quarter. Fortitude Family Office LLC now owns 578 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 55 shares during the last quarter. Finally, Sanders Morris Harris LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $777,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $230.71 on Wednesday. The stock has a market cap of $30.87 billion, a price-to-earnings ratio of 42.88 and a beta of 0.28. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $490.05. The firm has a 50-day moving average of $239.87 and a two-hundred day moving average of $272.67.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company’s quarterly revenue was up 66.9% compared to the same quarter last year. During the same period last year, the company posted ($0.51) earnings per share. On average, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.66 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Bank of America decreased their price target on Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating for the company in a research note on Tuesday, July 14th. Sanford C. Bernstein restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, August 31st. Barclays cut their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. Truist Financial cut their price objective on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Finally, UBS Group initiated coverage on Alnylam Pharmaceuticals in a research note on Thursday, October 15th. They issued a “buy” rating and a $354.00 target price on the stock. Four research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $364.95.

Insider Activity

In related news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.